AEterna Zentaris Inc. (AEZS)

[OhManIDied]

Earnings out:
http://finance.yahoo.com/news/aeterna-zentaris-reports-third-quarter-220000488.html

Strong fundamentals; dilution from Series B Warrants substantially ended

All amounts are in US Dollars

Third quarter key developments

Saizen® promotional activities show early promise
EstroGel® year-over-year new-prescription growth continues ahead of the market in the Company's territories
Zoptrex™ (zoptarelin doxorubicin) receives DSMB recommendation to continue ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data (after quarter end)
Zoptrex™ meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration- and Taxane-Resistant Prostate Cancer
Optimized Erk-Inhibitor Compound Selected for Further Development
Company announces restructuring of Financial Team and closing of Quebec City office (after quarter end)
Series B Share Purchase Warrants substantially eliminated (after quarter end)

AEZS

Zoptrex™ achieved its primary endpoint and demonstrated good tolerability during this early-stage study. The primary endpoint was Clinical Benefit, defined as remaining progression-free by RECIST and Prostate Specific Antigen after treatment for 12+ weeks. Shortly after quarter end, we received very encouraging news regarding Zoptrex™ when, following a comprehensive review of the final interim efficacy and safety data, the DSMB recommended that we continue the ZoptEC Phase 3 clinical study to its conclusion. We look forward to the successful completion of the clinical development of ZoptrexTM for our initial indication over the next year."